Comparative-effectiveness how-to
This article was originally published in The Gray Sheet
Executive Summary
Agency for Healthcare Research and Quality is circulating a 1draft guide for conducting comparative-effectiveness reviews of medical technology and treatments. The guide addresses key methodological issues and the assessment of evidence quality. Comparative-effectiveness research has become a hot topic among policymakers who see potential cost-savings from better informed treatment guidelines, and a Medicare package bill expected to be introduced this year could provide funding for a new comparative-effectiveness center (2"The Gray Sheet" Oct. 1, 2007, p. 12). Comments on AHRQ's draft guide are due Nov. 7
You may also be interested in...
Comparative Effectiveness Will Likely Appear In Medicare Package This Year
Creating a national infrastructure for comparative effectiveness research has been flagged as a priority for inclusion in a Medicare package that Congress could consider before the end of the year
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.